Bio-Rad Laboratories, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 4, 2026, reporting third-quarter net sales of $656.4 million and an operating loss driven in part by a $49.8 million impairment of purchased intangibles.

Key Highlights

  • Net sales: $656.4 million for the three months ended September 30, 2026, compared with $653.0 million in the same period of 2025, according to the filing.
  • Operating loss: The company reported a loss from operations of $49.7 million for Q3 2026, versus income from operations of $65.3 million in Q3 2025, as disclosed in the filing.
  • Intangibles impairment: The filing recorded an impairment of purchased intangibles of $49.8 million in the three months ended September 30, 2026, with no comparable charge in the prior-year quarter.
  • Fair value gains on equity securities: The filing reported gains from the change in fair market value of equity securities and loan receivable of $588.2 million for Q3 2026, compared with losses of $495.3 million in Q3 2025.
  • Nine-month net sales: $1,899.5 million for the nine months ended September 30, 2026, versus $1,890.0 million in the same period of 2025.
  • Total assets: $10,783.1 million as of September 30, 2026, up from $10,576.5 million at December 31, 2025, per the balance sheet.
  • Shares outstanding: As of October 30, 2026, Class A common stock outstanding was 21,832,130 shares and Class B common stock outstanding was 5,060,815 shares.

Bio-Rad Laboratories Q3 2026 Financial Results: Operations, Impairment, and Balance Sheet

Bio-Rad Laboratories, Inc. (NYSE:BIO, NYSE:BIO.B) disclosed its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2026. According to the filing, net sales for the third quarter were $656.4 million, a modest increase from $653.0 million in Q3 2025. For the nine-month period, net sales reached $1,899.5 million compared with $1,890.0 million in the same period of the prior year. Cost of goods sold rose to $327.8 million for the quarter from $309.6 million a year earlier, resulting in gross profit of $328.6 million versus $343.4 million in Q3 2025.

The company disclosed a loss from operations of $49.7 million for the three months ended September 30, 2026, compared with income from operations of $65.3 million in the year-ago quarter. The filing identifies a $49.8 million impairment charge on purchased intangibles in Q3 2026, with no corresponding charge in Q3 2025, as a significant contributor to this shift. Selling, general and administrative expense also increased to $257.1 million from $206.8 million year over year. Research and development expense was essentially flat at $71.4 million versus $71.3 million.

The filing reports a gain of $588.2 million from the change in fair market value of equity securities and loan receivable for Q3 2026, compared with a loss of $495.3 million in Q3 2025. The company noted other investments of $6,273.2 million on the balance sheet as of September 30, 2026, up from $6,103.6 million at December 31, 2025. Total stockholders' equity was $7,603.0 million at September 30, 2026, compared with $7,453.6 million at year-end 2025. Current maturities of long-term debt and notes payable rose significantly to $400.9 million from $1.3 million at December 31, 2025. The filing also notes that the company's forward-looking statements are subject to its cautionary language and various risk factors described in Part II, Item 1A.

What Was Disclosed

Bio-Rad Laboratories filed its Q3 2026 Form 10-Q covering the period ended September 30, 2026, disclosing an operating loss of $49.7 million, a $49.8 million intangibles impairment charge, net sales of $656.4 million, and a large fair-value gain on equity securities of $588.2 million for the quarter.